IDEAYA Biosciences’ (IDYA) “Outperform” Rating Reaffirmed at Royal Bank Of Canada

Royal Bank Of Canada reiterated their outperform rating on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a research note issued to investors on Wednesday morning,Benzinga reports. Royal Bank Of Canada currently has a $49.00 price target on the stock.

A number of other research firms also recently weighed in on IDYA. New Street Research set a $30.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. Wall Street Zen raised shares of IDEAYA Biosciences from a “hold” rating to a “buy” rating in a report on Sunday, November 9th. Wedbush increased their price target on IDEAYA Biosciences from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Wednesday. Guggenheim restated a “buy” rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday. Finally, The Goldman Sachs Group lifted their price objective on IDEAYA Biosciences from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 21st. Fifteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.60.

IDEAYA Biosciences Stock Up 0.5%

Shares of IDYA opened at $30.92 on Wednesday. The stock’s fifty day simple moving average is $34.25 and its 200-day simple moving average is $30.44. The firm has a market capitalization of $2.71 billion, a PE ratio of -23.60 and a beta of 0.10. IDEAYA Biosciences has a 12-month low of $13.45 and a 12-month high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.09. The firm had revenue of $21.75 million for the quarter, compared to the consensus estimate of $5.95 million. During the same period in the prior year, the firm posted ($1.49) earnings per share. The business’s revenue for the quarter was up 55.7% compared to the same quarter last year. Analysts anticipate that IDEAYA Biosciences will post -3.07 EPS for the current year.

Hedge Funds Weigh In On IDEAYA Biosciences

Several institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its stake in IDEAYA Biosciences by 30.1% during the 1st quarter. Royal Bank of Canada now owns 122,460 shares of the company’s stock worth $2,006,000 after purchasing an additional 28,322 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of IDEAYA Biosciences by 8.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,044 shares of the company’s stock valued at $938,000 after buying an additional 4,308 shares during the period. Millennium Management LLC boosted its holdings in shares of IDEAYA Biosciences by 345.2% in the first quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock valued at $8,970,000 after buying an additional 424,625 shares during the period. Vanguard Personalized Indexing Management LLC bought a new stake in shares of IDEAYA Biosciences during the second quarter worth $216,000. Finally, CWM LLC raised its holdings in shares of IDEAYA Biosciences by 33.0% during the second quarter. CWM LLC now owns 3,153 shares of the company’s stock worth $66,000 after acquiring an additional 782 shares during the period. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences News Roundup

Here are the key news stories impacting IDEAYA Biosciences this week:

• Positive Sentiment: Q4 / FY2025 results beat expectations: EPS loss was narrower than consensus (‑$0.94 vs. ‑$1.03 est.) and revenue came in well above estimates at $21.75M (vs. ~$5.95M est.), with revenue up ~56% year‑over‑year — a tangible near-term fundamental beat. Q4 Press Release
• Positive Sentiment: Pipeline and readout timing bolsters near-term catalyst visibility: 130 required PFS events were confirmed by BICR in the Phase 2/3 OptimUM‑02 darovasertib + crizotinib trial and topline results are expected by roughly the last week of March; darovasertib is planned for three randomized Phase 3 registrational trials by H1 2026. Business Update / PR Newswire
• Positive Sentiment: ADC program (IDE849) progress and milestones: company expects to initiate a registrational IDE849 monotherapy study in 2L+ SCLC/NEC by end of 2026 and to provide preliminary IDE849 Phase 1 data by year‑end — potential medium‑term value drivers if clinical data are positive. Business Update / PR Newswire
• Positive Sentiment: Strong balance sheet: ~ $1.05B in cash, cash equivalents and marketable securities as of 12/31/2025, which management says should fund operations into 2030 — lowers near‑term financing risk. Business Update / PR Newswire
• Positive Sentiment: Analyst price-target lifts: Wedbush raised its target to $52 (outperform), Guggenheim reaffirmed buy with $50 PT, and RBC reaffirmed outperform with a $49 PT — these raise upside expectations and can support investor sentiment. Wedbush note Guggenheim note RBC / Benzinga
• Neutral Sentiment: Management presentation at Citi’s 2026 Virtual Oncology Leadership Summit provided additional corporate and program-level color (transcript available) but contained no new timing surprises beyond the company release. Citi Summit Transcript

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.